ReviewF1000Research2017
Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies.
Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- The Mitochondrial Foundations of Parkinson's Disease: Therapeutic Implications.Aging and disease · 2025Review
- Investigation of the genetic aetiology of Lewy body diseases with and without dementia.Brain communications · 2024Article
- Progression of brain cholinergic dysfunction in patients with isolated rapid eye movement sleep behavior disorder.European journal of neurology · 2024Article
- Investigation of the genetic aetiology of Lewy body diseases with and without dementia.medRxiv : the preprint server for health sciences · 2023Article
- Morphological characteristics differentiate dementia with Lewy bodies from Parkinson disease with and without dementia.Journal of neural transmission (Vienna, Austria : 1996) · 2023Article
- α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies.Translational neurodegeneration · 2023Review
- Role of piRNA biogenesis and its neuronal function in the development of neurodegenerative diseases.Frontiers in aging neuroscience · 2023Review
- The Complex Mechanisms by Which Neurons Die Following DNA Damage in Neurodegenerative Diseases.International journal of molecular sciences · 2022Review
- High-Throughput Sequencing Haplotype Analysis Indicates inLife (Basel, Switzerland) · 2022Article
- Lewy body disease or diseases with Lewy bodies?NPJ Parkinson's disease · 2022Review
- Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases.Acta neuropathologica · 2021Article
- Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases.Journal of neural transmission (Vienna, Austria : 1996) · 2021Article
- Downregulation of microRNA-15b-5p Targeting the Akt3-Mediated GSK-3BioMed research international · 2021Article
- Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.Frontiers in cardiovascular medicine · 2021Article
- Mitochondria-Microbiota Interaction in Neurodegeneration.Frontiers in aging neuroscience · 2021Review
- The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson's Disease.Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition · 2020Article
- The Impact of Chronic Intestinal Inflammation on Brain Disorders: the Microbiota-Gut-Brain Axis.Molecular neurobiology · 2019Review
- Use of Ceftriaxone in Treating Cognitive and Neuronal Deficits Associated With Dementia With Lewy Bodies.Frontiers in neuroscience · 2019Article
- Increased weighting on prior knowledge in Lewy body-associated visual hallucinations.Brain communications · 2019Article
- Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) are relentlessly progressive neurodegenerative disorders that are likely to represent two ends of a disease spectrum. It is well established that both are characterised pathologically by widespread cortical Lewy body deposition. However, until recently, the pathophysiological mechanisms leading to neuronal damage were not known. It was also not understood why some cells are particularly vulnerable in PDD/DLB, nor why some individuals show more aggressive and rapid dementia than others. Recent studies using animal and cell models as well as human post-mortem analyses have provided important insights into these questions. Here, we review recent developments in the pathophysiology in PDD/DLB. Specifically, we examine the role of pathological proteins other than α-synuclein, consider particular morphological and physiological features that confer vulnerabilities on some neurons rather than others, and finally examine genetic factors that may explain some of the heterogeneity between individuals with PDD/DLB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.